These lower grade lesions frequently progress according to the so-called clinical secondary glioblastoma pathway to grade IV lesions, and are strongly associated with mutations in the isocitrate dehydrogenase genes (IDH1, and rarely, IDH2), lower age of onset, and better prognosis [2]. Here, IDH1 is linked to glioblastoma.